CHIP Tied to Higher CVD Risk in Patients With Multiple Myeloma Undergoing HCT
Researchers of a study investigating the role of clonal hematopoiesis of indeterminate potential (CHIP) in cardiovascular disease (CVD) among patients with multiple myeloma (MM) undergoing hematopoietic stem cell...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
MS, RN, ACNP-BC, AOCN
Nurse Practitioner, Associate Clinical Professor, University of California San Francisco
Patient Management Guidelines
National Comprehensive Cancer Network Clinical Practice Guidelines
The National Comprehensive Cancer Network Clinical Practice Guidelines has evidence-based guidance on the diagnosis, workup, and management of multiple myeloma.
These guidelines provide recommendations on treatment for both patients who are newly diagnosed with multiple myeloma and patients who have relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.
Revealing Multiple Myeloma Origins: Premalignant Disorders and Biomarker Advances
Preexisting plasma cell disorders, such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), are identified in at least one-third of patients with multiple myeloma (MM)....
Challenges and Hope in Treating RRMM: Insights from the LocoMMotion Study
Researchers from the LocoMMotion study examined real-world clinical practice treatments for patients with relapsed/refractory multiple myeloma (RRMM) exposed to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies....
Multiple Myeloma Advances Call for Standardized IgG-RT to Tackle Immune Challenges
Recent advancements in multiple myeloma (MM) therapies have extended survival but introduced immunosuppressive challenges, including hypogammaglobulinemia, which increases infection risk. T-cell engaging therapies have improved outcomes for heavily pretreated patients,...
Talquetamab Shows Promising Efficacy and Manageable Safety Profile in Relapsed/Refractory Multiple Myeloma
Talquetamab, a bispecific antibody targeting GPRC5D, demonstrated over 71% overall response rates in the MonumenTAL-1 trial for patients with triple-class exposed relapsed/refractory multiple myeloma....
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
